1 型神經纖維瘤市場規模、佔有率和成長分析：按疾病、療法、分銷管道、最終用戶、患者群體和地區分類－2026-2033 年產業預測

2024 年全球 1 型神經纖維瘤市場價值為 82.4 億美元，預計到 2033 年將從 2025 年的 90.3 億美元成長至 188 億美元，預測期（2026-2033 年）的複合年成長率為 9.6%。

由於人們對1型神經纖維瘤（NF1）的認知不斷提高以及基因診斷技術的進步，全球NF1市場正經歷顯著成長。 NF1曾被歸類為罕見疾病，但隨著分子定序發現更多病例，患者數量正在增加。獲得FDA批准的有效療法的推出，吸引了投資者的關注，並為新療法的研發提供了資金籌措支持。生物製藥的興起以及保險公司有利的報銷政策進一步加速了這一進程，提高了患者的就醫便利性並增加了收入。此外，人工智慧驅動的診斷技術顯著提高了腫瘤徵兆​​的檢測能力，並簡化了臨床試驗流程，從而創造了更有效率的醫療保健環境。這些創新療法和先進診斷工具的協同效應，進一步促進了NF1市場的成長和投資者的信心。

全球1型神經纖維瘤市場成長要素

全球臨床試驗活動的激增顯著擴大了患者入組機會，並促進了合作研究網路的形成。這加速了1型神經纖維瘤創新療法的評估，打造了一條前景廣闊的治療產品線，吸引了製藥業的投資者關注和投資。因此，這種環境推動了關鍵支援服務的發展，促進了整體市場成長，並增強了全球持續擴張的前景。此外，這些趨勢透過增強臨床醫生對新療法的信心和促進患者支持活動，進一步加速了市場發展勢頭。

全球1型神經纖維瘤市場的限制因素

全球1型神經纖維瘤市場受到不同醫療體系報銷政策不一致的限制。這限制了患者獲得新療法的機會，也為生產商的潛在收入帶來了不確定性。這種財務障礙阻礙了對先進產品平臺的投資，限制了創新療法的引入，迫使醫療服務提供者優先考慮更具成本效益的替代方案。因此，這種情況阻礙了市場成長，並降低了在該治療領域進行突破性研究的意願。此外，患者往往面臨高額的自付費用，這使得持續治療變得困難，並對長期健康結果產生負面影響，進一步加劇了該市場面臨的挑戰。

1型神經纖維瘤全球市場趨勢

在全球1型神經纖維瘤）市場，隨著醫療服務提供者將早期識別NF1基因突變作為主動疾病管理的首要任務，整合基因篩檢正成為顯著趨勢。這一趨勢的促進因素包括：人們對NF1的認知度不斷提高、次世代定序技術的進步以及對個人化治療方案的重視。早期檢測能夠實現及時治療性介入，最大限度地減少併發症，改善患者的長期預後，從而帶來更可預測的醫療體驗。因此，製造商正透過調整產品開發策略以整合診斷功能、促進與基因檢測實驗室的合作以及擴大精準醫療解決方案的覆蓋範圍，最終鞏固其在全球市場的地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

1 型神經纖維瘤全球市場規模：依疾病類型分類

• 網狀神經纖維瘤
• 皮膚神經纖維瘤
• 視神經通路膠質瘤
• 骨骼症狀
• 其他症狀

1 型神經纖維瘤全球市場規模：依治療類型分類

• 標靶治療
  • Selumetinib（Coselgo）
  • 其他MEK抑制劑
• 手術切除
• 化療
• 放射線治療
• 支持性護理
• 基因療法（新興）

1 型神經纖維瘤全球市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

1 型神經纖維瘤全球市場規模：依最終用戶分類

• 醫院
• 專科診所
• 門診手術中心

1 型神經纖維瘤全球市場規模：依患者群體分類

• 兒童
• 成人

1 型神經纖維瘤全球市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AstraZeneca PLC（MedImmune/Alexion）
• Novartis AG
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi SA
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Springworks Therapeutics, Inc.
• DeCiphera Pharmaceuticals LLC
• Focus Pharma Holdings Inc.
• Leo Pharma A/S
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Incyte Corporation

結論與建議

Global Neurofibromatosis Type 1 Market size was valued at USD 8.24 Billion in 2024 and is poised to grow from USD 9.03 Billion in 2025 to USD 18.8 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global Neurofibromatosis Type 1 (NF1) market is witnessing significant growth due to an increasing recognition of the condition and advancements in genetic diagnostics. Previously classified as an orphan disease, NF1's patient population is expanding as molecular sequencing reveals more cases. The introduction of effective therapies, supported by successful FDA approvals, has attracted investor interest and funding for new treatments. This evolution is further accelerated by the emergence of biologics and favorable payer reimbursement policies, enhancing patient access and boosting sales. Additionally, AI-driven diagnostics significantly improve the detection of tumor manifestations and streamline clinical trial processes, fostering a more efficient healthcare landscape. This synergy of innovative therapies and enhanced diagnostic tools continues to amplify NF1 market growth and investor confidence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurofibromatosis Type 1 market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurofibromatosis Type 1 Market Segments Analysis

Global neurofibromatosis type 1 market is segmented by disease type, treatment type, distribution channel, end user, patient population and region. Based on disease type, the market is segmented into Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Pathway Gliomas, Skeletal Manifestations and Other Manifestations. Based on treatment type, the market is segmented into Targeted Therapy, Surgical Resection, Chemotherapy, Radiation Therapy, Supportive Care and Gene Therapy (Emerging). Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Ambulatory Surgical Centers. Based on patient population, the market is segmented into Pediatric and Adult. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurofibromatosis Type 1 Market

The increased activity in clinical trials around the world has significantly improved the opportunities for patient enrollment and encouraged the formation of collaborative research networks. This has expedited the assessment of innovative therapies for neurofibromatosis type 1, leading to a promising pipeline of treatments that capture investor interest and draw in pharmaceutical investments. Consequently, this environment is fostering the development of essential supportive services, contributing to overall market growth and enhancing prospects for sustained expansion globally. Additionally, these trends bolster clinician confidence in new treatment options and support patient advocacy efforts, further energizing market momentum.

Restraints in the Global Neurofibromatosis Type 1 Market

The global market for Neurofibromatosis Type 1 is hindered by inconsistent reimbursement policies across various healthcare systems, which limit patient access to new treatments and create uncertainty for manufacturers about potential revenue. This financial barrier discourages investment in advanced product pipelines, restricting the adoption of innovative therapies and leading healthcare providers to favor more cost-effective alternatives. Consequently, this situation hampers market growth and diminishes motivation for groundbreaking research within this therapeutic area. Furthermore, patients often encounter out-of-pocket expenses that complicate continual treatment and adversely affect long-term health outcomes, compounding the challenges faced in this market.

Market Trends of the Global Neurofibromatosis Type 1 Market

The Global Neurofibromatosis Type 1 market is witnessing a notable trend towards integrated genetic screening, as healthcare providers prioritize early identification of NF1 mutations for proactive disease management. This trajectory is fueled by heightened awareness of NF1, advancements in next-generation sequencing technology, and an emphasis on personalized treatment pathways. Early detection facilitates timely therapeutic interventions, minimizes complications, and enhances long-term patient outcomes, resulting in a more predictable healthcare experience. Consequently, manufacturers are aligning their product development strategies with diagnostic integration, fostering collaborations with genetic laboratories and broadening access to precision-focused care solutions, ultimately strengthening their market positions globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Neurofibromatosis Type 1 Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Plexiform Neurofibromas
• Cutaneous Neurofibromas
• Optic Pathway Gliomas
• Skeletal Manifestations
• Other Manifestations

Global Neurofibromatosis Type 1 Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
  • Selumetinib (Koselugo)
  • Other MEK Inhibitors
• Surgical Resection
• Chemotherapy
• Radiation Therapy
• Supportive Care
• Gene Therapy (Emerging)

Global Neurofibromatosis Type 1 Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Neurofibromatosis Type 1 Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Global Neurofibromatosis Type 1 Market Size by Patient Population & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult

Global Neurofibromatosis Type 1 Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca PLC (MedImmune/Alexion)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Springworks Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DeCiphera Pharmaceuticals LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Focus Pharma Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations